Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 35HER2-positive Breast Cancer 3Brain Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Motor Activity 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Invasive Breast Cancer 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1

Interventions

Radiotherapy 2toripalimab 1pertuzumab 1lorlatinib 1azeliragon 1adavosertib 1Trastuzumab 1Radiation 1Pemetrexed 1Immunotherapy, Adoptive 1GDC-0084 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Meningeal Carcinomatosis × pertuzumab × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡